RÉSUMÉ
Left ventricular diastolic dysfunction (LVDD) is the predominant cardiac abnormality in cirrhosis. We investigated the association of LVDD with systemic inflammation and its impact on renal function, occurrence of hepatorenal syndrome (HRS) and survival in patients with cirrhosis and ascites. We prospectively enrolled 215 patients with cirrhosis and ascites. We evaluated the diagnosis and grading of LVDD by Doppler echocardiography, inflammatory markers, systemic hemodynamics, vasoactive factors, radioisotope-assessed renal function and blood flow, HRS development and liver-related mortality. LVDD was diagnosed in 142 (66%) patients [grade 2/3: n â =â 61 (43%)]. Serum lipopolysaccharide-binding protein (LBP), plasma renin activity (PRA) and glomerular filtration rate (GFR) were independently associated with the presence of grade 2/3 LVDD and the severity of diastolic dysfunction. Serum tumor necrosis factor-α, cardiac output and plasma noradrenaline were also independently associated with the presence of grade 2/3 LVDD. The diastolic function marker E / e ' was strongly correlated with serum LBP ( r â =â 0.731; P â <â 0.001), PRA ( r â =â 0.714; P â <â 0.001) and GFR ( r â =â -0.609; P â <â 0.001) among patients with LVDD. The 5-year risk of HRS development and death was significantly higher in patients with grade 2/3 LVDD compared to those with grade 1 (35.5 vs. 14.4%; P â =â 0.01 and 53.3 vs. 28.2%; P â =â 0.03, respectively). The occurrence and severity of LVDD in patients with cirrhosis and ascites is closely related to inflammatory activity. Advanced LVDD is associated with baseline circulatory and renal dysfunction, favoring HRS development, and increased mortality.
Sujet(s)
Protéine de la phase aigüe , Ascites , Marqueurs biologiques , Débit de filtration glomérulaire , Syndrome hépatorénal , Cirrhose du foie , Glycoprotéines membranaires , Dysfonction ventriculaire gauche , Humains , Femelle , Mâle , Cirrhose du foie/complications , Cirrhose du foie/mortalité , Cirrhose du foie/physiopathologie , Adulte d'âge moyen , Dysfonction ventriculaire gauche/physiopathologie , Dysfonction ventriculaire gauche/mortalité , Syndrome hépatorénal/mortalité , Syndrome hépatorénal/physiopathologie , Syndrome hépatorénal/étiologie , Ascites/étiologie , Ascites/physiopathologie , Ascites/mortalité , Études prospectives , Sujet âgé , Marqueurs biologiques/sang , Indice de gravité de la maladie , Échocardiographie-doppler , Facteurs de risque , Adulte , Pronostic , Inflammation/sang , Rein/physiopathologie , Médiateurs de l'inflammation/sang , Protéines de transport/sang , Diastole , Rénine/sangRÉSUMÉ
Background: Hepatorenal syndrome (HRS) is the deadliest complication of cirrhosis. The purpose of this study is to analyze if the use of a protocol for HRS is associated with higher survival in these patients.Methods: An evidence-based protocol for the diagnosis and treatment of HRS was instituted in 2013. Data from medical records from 2010 to 2016 were obtained by searching the hospital database for patients who received terlipressin, in the three years before and after the institution of the protocol. Data were reviewed to confirm the diagnosis of HRS and multiple variables were collected. Liver-specific scores were calculated and a stepwise Cox regression approach was used for univariate and multivariate analysis.Results: The study included 46 patients, 20 from the pre-protocol period and 26 from the post-protocol period. Respectively, mortality at 30 days, 90 days and 365 days was 75%, 75% and 90% for the pre-protocol period, and 61%, 69% and 80% for the post-protocol period. In the multivariate analysis, an aspartate aminotransferase (AST) of <40U/L, the pre-protocol period and higher Child-Turcotte-Pugh scores were associated with higher 30-day and 90-day mortality. The total mean dose of terlipressin and human albumin used per patient was reduced from 27mg to 22mg and from 236g to 144g, respectively, after the institution of the protocol. This was not associated with higher mortality.Conclusion: The use of an evidence-based protocol for the treatment of HRS translated into a higher survival. The authors suggest that the use of evidence-based protocols for the diagnosis and treatment of HRS could reduce cost and mortality in tertiary hospitals.
Antecedentes: El síndrome hepatorrenal (SHR) es la complicación más mortal de la cirrosis. El objetivo de este estudio es analizar si el uso de un protocolo para el SHR se asocia a una mayor supervivencia en estos pacientes.Métodos: En 2013 se instituyó un protocolo basado en la evidencia para el diagnóstico y tratamiento del SHR. Los datos de los registros médicos del 2010 al 2016 se obtuvieron mediante la búsqueda en la base de datos del hospital de pacientes que recibieron terlipresina, 3 años antes y después de la institución del protocolo. Se revisaron los datos para confirmar el diagnóstico de SHR y se recopilaron múltiples variables. Se calcularon las puntuaciones específicas del hígado y se utilizó un enfoque gradual de la regresión de Cox para el análisis univariado y multivariado.Resultados: Se incluyó a 46 pacientes, 20 del período preprotocolo y 26 posprotocolo. Respectivamente, la mortalidad a los 30, 90 y 365 días fue del 75, el 75 y el 90%, respectivamente, para el período previo al protocolo y del61, el 69 y el 80%, respectivamente, para el posterior al protocolo. En el análisis multivariado, aspartato aminotransferasa (AST) <40 U/l, el período preprotocolo y las puntuaciones más altas de Child-Turcotte-Pugh se asociaron con una mayor mortalidad a los 30 y 90 días. Las dosis media total de terlipresina y albúmina humana utilizada por paciente se redujo de 27 a 22mg de terlipresina y de 236 a 144g de albúmina humana después de la institución del protocolo. Esto no se asoció con una mayor mortalidad.Conclusión: El uso de un protocolo basado en la evidencia para el tratamiento del SHR se tradujo en una mayor supervivencia. Los autores sugieren que el uso de protocolos basados en la evidencia para el diagnóstico y tratamiento del SHR podría reducir el costo y la mortalidad en los hospitales de tercer nivel.
Sujet(s)
Humains , Protocoles cliniques , Syndrome hépatorénal/diagnostic , Syndrome hépatorénal/traitement médicamenteux , Syndrome hépatorénal/prévention et contrôle , Fibrose , Mortalité hospitalière , Syndrome hépatorénal/mortalité , Patients , Patients hospitalisés , Gastroentérologie , Interprétation statistique de données , Aspartate aminotransferases , TerlipressineRÉSUMÉ
BACKGROUND: Hepatorenal syndrome (HRS) is the deadliest complication of cirrhosis. The purpose of this study is to analyze if the use of a protocol for HRS is associated with higher survival in these patients. METHODS: An evidence-based protocol for the diagnosis and treatment of HRS was instituted in 2013. Data from medical records from 2010 to 2016 were obtained by searching the hospital database for patients who received terlipressin, in the three years before and after the institution of the protocol. Data were reviewed to confirm the diagnosis of HRS and multiple variables were collected. Liver-specific scores were calculated and a stepwise Cox regression approach was used for univariate and multivariate analysis. RESULTS: The study included 46 patients, 20 from the pre-protocol period and 26 from the post-protocol period. Respectively, mortality at 30 days, 90 days and 365 days was 75%, 75% and 90% for the pre-protocol period, and 61%, 69% and 80% for the post-protocol period. In the multivariate analysis, an aspartate aminotransferase (AST) of <40U/L, the pre-protocol period and higher Child-Turcotte-Pugh scores were associated with higher 30-day and 90-day mortality. The total mean dose of terlipressin and human albumin used per patient was reduced from 27mg to 22mg and from 236g to 144g, respectively, after the institution of the protocol. This was not associated with higher mortality. CONCLUSION: The use of an evidence-based protocol for the treatment of HRS translated into a higher survival. The authors suggest that the use of evidence-based protocols for the diagnosis and treatment of HRS could reduce cost and mortality in tertiary hospitals.
Sujet(s)
Protocoles cliniques , Médecine factuelle , Syndrome hépatorénal , Terlipressine/usage thérapeutique , Vasoconstricteurs/usage thérapeutique , Albumines/administration et posologie , Analyse de variance , Aspartate aminotransferases/sang , Femelle , Syndrome hépatorénal/diagnostic , Syndrome hépatorénal/traitement médicamenteux , Syndrome hépatorénal/enzymologie , Syndrome hépatorénal/mortalité , Humains , Mâle , Adulte d'âge moyen , Modèles des risques proportionnels , Centres de soins tertiairesRÉSUMÉ
INTRODUCTION AND OBJECTIVES: Since MELD implementation renal impairment in liver transplant (LT) recipients has become of increasing importance. This is the first study evaluating the course of renal function immediately prior to LT as predictor for long-term renal and overall outcome. PATIENTS AND METHODS: In this retrospective study, 226 adults undergoing LT at the University Medical Center Hamburg-Eppendorf (2011-2015) were included. The impact of renal function over a period of 3 months prior to LT compared to renal function at the day of LT on long-term renal outcome and survival was assessed. RESULTS: According to GFR at day of LT renal function improved (≥1 CKD stage) in 64 patients (28%), remained stable in 144 (64%) or deteriorated in 18 (8%). Improvement of renal function prior to LT did neither significantly affect 90-day (13% vs. 14%, p = 0.83), nor 5-year post-LT mortality (35% vs. 41%, p = 0.57). 50 patients (22%) with hepatorenal syndrome (HRS) received terlipressin prior to LT, but only 18 (37%) showed prolonged stabilization of renal function (improvement ≥1 CKD stage). Response to terlipressin did neither improve 90-day (p=1), 5-year mortality (p = 0.52) nor long-term renal function (p = 0.843). Nevertheless, need for dialysis pre-LT (59% vs. 34%, p = 0.005) and post-LT (62% vs. 17%, p<0.001) was associated with increased 5-year mortality. CONCLUSIONS: Improvement of renal function immediately prior to LT, either spontaneously or following terlipressin therapy, did neither ameliorate long-term renal outcome nor survival in LT recipients. Future studies need to clarify the impact of terlipressin in HRS on the transplant waiting time in LT candidates.
Sujet(s)
Débit de filtration glomérulaire/physiologie , Syndrome hépatorénal/chirurgie , Rein/physiopathologie , Transplantation hépatique , Sujet âgé , Femelle , Études de suivi , Allemagne/épidémiologie , Syndrome hépatorénal/mortalité , Syndrome hépatorénal/physiopathologie , Humains , Mâle , Adulte d'âge moyen , Période préopératoire , Études rétrospectives , Facteurs de risque , Taux de survie/tendances , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe. METHODS: We conducted a phase 3 trial to confirm the efficacy and safety of terlipressin plus albumin in adults with HRS-1. The patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days; in both groups, concomitant use of albumin was strongly recommended. The primary end point was verified reversal of HRS, defined as two consecutive serum creatinine measurements of 1.5 mg per deciliter or less at least 2 hours apart and survival without renal-replacement therapy for at least 10 days after the completion of treatment. Four prespecified secondary end points were analyzed with the Hochberg procedure to account for multiple comparisons. RESULTS: A total of 300 patients underwent randomization - 199 were assigned to the terlipressin group and 101 to the placebo group. Verified reversal of HRS was reported in 63 patients (32%) in the terlipressin group and 17 patients (17%) in the placebo group (P = 0.006). With respect to the prespecified secondary end points, HRS reversal, defined as any serum creatinine level of 1.5 mg per deciliter or less during the first 14 days, was reported in 78 patients (39%) in the terlipressin group and 18 (18%) in the placebo group (P<0.001); HRS reversal without renal-replacement therapy by day 30, in 68 (34%) and 17 (17%), respectively (P = 0.001); HRS reversal among patients with systemic inflammatory response syndrome (84 patients in the terlipressin group and 48 patients in the placebo group), in 31 (37%) and 3 (6%), respectively (P<0.001); and verified reversal of HRS without recurrence by day 30, in 52 (26%) and 17 (17%), respectively (P = 0.08). At day 90, liver transplantations had been performed in 46 patients (23%) in the terlipressin group and 29 patients (29%) in the placebo group, and death occurred in 101 (51%) and 45 (45%), respectively. More adverse events, including abdominal pain, nausea, diarrhea, and respiratory failure, occurred with terlipressin than with placebo. Death within 90 days due to respiratory disorders occurred in 22 patients (11%) in the terlipressin group and 2 patients (2%) in the placebo group. CONCLUSIONS: In this trial involving adults with cirrhosis and HRS-1, terlipressin was more effective than placebo in improving renal function but was associated with serious adverse events, including respiratory failure. (Funded by Mallinckrodt Pharmaceuticals; CONFIRM ClinicalTrials.gov number, NCT02770716.).
Sujet(s)
Syndrome hépatorénal/traitement médicamenteux , Terlipressine/usage thérapeutique , Vasoconstricteurs/usage thérapeutique , Albumines/usage thérapeutique , Association thérapeutique , Méthode en double aveugle , Femelle , Syndrome hépatorénal/étiologie , Syndrome hépatorénal/mortalité , Humains , Perfusions veineuses , Cirrhose du foie/complications , Transplantation hépatique , Mâle , Adulte d'âge moyen , Traitement substitutif de l'insuffisance rénale , Insuffisance respiratoire/induit chimiquement , Terlipressine/effets indésirables , Résultat thérapeutique , Vasoconstricteurs/effets indésirablesRÉSUMÉ
BACKGROUND: Hepatorenal syndrome and acute kidney injury are common complications of decompensated cirrhosis, and terlipressin is recommended as first-line vasoconstrictor therapy. However, data on its use outside of clinical trials are lacking. AIMS: To assess practice patterns and outcomes around vasoconstrictor use for hepatorenal syndrome in UK hospitals. METHODS: This was a multicentre chart review study. Data were extracted from medical records of patients diagnosed with hepatorenal syndrome and treated by vasoconstrictor drugs between January 2013 and December 2017 at 26 hospitals in the United Kingdom. The primary outcome was improvement of kidney function, defined as complete response (serum creatinine improved to ≤1.5 mg/dL), partial response (serum creatinine reduction of ≥20% but >1.5 mg/dL) and overall response (complete or partial response). Other outcomes included need for dialysis, mortality, liver transplantation and adverse events. RESULTS: Of the 225 patients included in the analysis, 203 (90%) were treated with terlipressin (median duration, 6 days; range: 2-24 days). Mean (±standard deviation) serum creatinine at vasopressor initiation was 3.25 ± 1.64 mg/dL. Terlipressin overall response rate was 73%. Overall response was higher in patients with mild acute kidney injury (baseline serum creatinine <2.25 mg/dL), compared to those with moderate (serum creatinine ≥2.25 mg/dL and <3.5 mg/dL) or severe (serum creatinine ≥3.5 mg/dL). Ninety-day survival was 86% for all patients (93% for overall responders vs 66% for treatment nonresponders, P < 0.0001). CONCLUSION: Terlipressin is the most commonly prescribed vasoconstrictor for patients with hepatorenal syndrome in the United Kingdom. Treatment with terlipressin in patients with less severe acute kidney injury (serum creatinine <2.25 mg/dL) was associated with higher treatment responses, and 90-day survival.
Sujet(s)
Syndrome hépatorénal/thérapie , Terlipressine/usage thérapeutique , Vasoconstricteurs/usage thérapeutique , Adulte , Sujet âgé , Créatinine/sang , Femelle , Syndrome hépatorénal/sang , Syndrome hépatorénal/mortalité , Humains , Transplantation hépatique , Mâle , Adulte d'âge moyen , Dialyse rénale , Résultat thérapeutique , Royaume-UniRÉSUMÉ
BACKGROUND: It has been reported that transjugular intrahepatic portosystemic shunting (TIPS) might be utilized as a salvage option for hepatorenal syndrome (HRS), while randomized controlled trials are pending and real-world contemporary data on inpatient mortality is lacking. METHODS: We conducted an observational retrospective cohort study from the National Inpatient Sample from 2005 to 2014. We included all adult patients admitted with HRS and cirrhosis, using ICD 9-CM codes. We excluded cases with variceal bleeding, Budd-Chiari, end-stage renal disease, liver transplant and transfers to acute-care facilities. TIPS' association with inpatient mortality was assessed using multivariable mixed-effects logistic regression, as well as exact-matching, thus mitigating for TIPS selection bias. The exact-matched analysis was repeated among TIPS-only versus dialysis-only patients. RESULTS: A total of 79,354 patients were included. Nine hundred eighteen (1.2%) underwent TIPS. Between TIPS and non-TIPS groups, mean age (58 years) and gender (65% males) were similar. Overall mortality was 18% in TIPS and 48% in dialysis-only cases (n = 10,379; 13.1%). Ninety six (10.5%) TIPS patients underwent dialysis. In-hospital mortality in TIPS patients was twice less likely than in non-TIPS patients (adjusted odds ratio [aOR] = 0.43, 95% CI 0.30-0.62; p < 0.001), with similar results in matched analysis [exact-matched (em) OR = 0.39, 95% CI 0.17-0.89; p < 0.024; groups = 96; unweighted n = 463]. Head-to-head comparison showed that TIPS-only patients were 3.3 times less likely to succumb inpatient versus dialysis-only patients (contrast aOR = 0.31, 95% CI 0.20-0.46; p < 0.001), with similar findings post-matching (emOR = 0.22, 95% CI 0.15-0.33; p < 0.001; groups = 54, unweighted n = 1457). CONCLUSIONS: Contemporary, real-world data reveal that TIPS on its own, and when compared to dialysis, is associated with decreased inpatient mortality when utilized in non-bleeders-HRS patients. Further randomized studies are needed to establish the long-term benefit of TIPS in these patients.
Sujet(s)
Syndrome hépatorénal/mortalité , Syndrome hépatorénal/chirurgie , Mortalité hospitalière , Anastomose portosystémique intrahépatique par voie transjugulaire/mortalité , Femelle , Humains , Mâle , Adulte d'âge moyen , Études rétrospectives , Thérapie de rattrapage , États-UnisRÉSUMÉ
OBJECTIVES: Spontaneous splenorenal shuntis a type of portosystemic shunt that develops frequently in the setting of chronic portal hypertension. It remains controversial whether shuntinterventions during liver transplant improve transplant outcomes. MATERIALS AND METHODS: We conducted a retrospective comparison between deceased-donor liver transplant recipients who received spontaneous splenorenal shunt intervention and those who did not at a tertiary center between 2012 and 2017. Primary outcomes of interest included intraoperative transfusion requirement, hospital length of stay, acute kidney injury posttransplant, portal vein thrombosis, thrombocytopenia, and 1-year graft and patient survival. RESULTS: Of 268 liver transplant recipients, 50 (18.6%) had large spontaneous splenorenal shunts pretransplant, with 45 patients having available radiologic and outcome data. Nine of 45 patients (20%) received shunt intervention, including pretransplant balloonoccluded retrograde transvenous obliteration (n = 5), intraoperative ligation of the left renal vein (n = 3), and intraoperative direct shunt ligation (n = 1). Demographic data, clinical characteristics, and Model for End-Stage Liver Disease scores were not different between the intervention and the nonintervention groups. Intraoperative transfusion, length of hospitalization, portal vein thrombosis, thrombocytopenia, and 1-year graft and patient survival were also similar between the 2 groups. However, the rate of posttransplant acute kidney injury was significantly lower in patients in the intervention group (0 cases vs 12 cases; odds ratio = 0.73; 95% confidence interval, 0.59-0.90). Patients with no SRS intervention (n = 36) were followed radiologically for 1 year posttransplant, with follow-up data showing complete resolution of spontaneous splenorenal shunt in just 4 patients (15%) and no changes in the remaining patients. CONCLUSIONS: Peritransplant interventions for spontaneous splenorenal shunt may reduce posttransplant acute kidney injury. In patients without intervention, spontaneous splenorenal shunt predominantly persisted 1 year posttransplant.
Sujet(s)
Atteinte rénale aigüe/prévention et contrôle , Syndrome hépatorénal/chirurgie , Défaillance rénale chronique/chirurgie , Transplantation hépatique/effets indésirables , Veines rénales/chirurgie , Veine liénale/chirurgie , Atteinte rénale aigüe/diagnostic , Atteinte rénale aigüe/mortalité , Adulte , Sujet âgé , Femelle , Syndrome hépatorénal/imagerie diagnostique , Syndrome hépatorénal/mortalité , Syndrome hépatorénal/physiopathologie , Humains , Incidence , Défaillance rénale chronique/imagerie diagnostique , Défaillance rénale chronique/mortalité , Défaillance rénale chronique/physiopathologie , Transplantation hépatique/mortalité , Mâle , Adulte d'âge moyen , Veines rénales/imagerie diagnostique , Veines rénales/physiopathologie , Études rétrospectives , Facteurs de risque , Veine liénale/imagerie diagnostique , Veine liénale/physiopathologie , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
INTRODUCTION: Type 1 hepatorenal syndrome (HRS) is a fatal complication of cirrhosis. Treatments trend toward HRS reversal, but few show clear mortality benefit. We sought to quantify the progress-or lack thereof-in improving outcomes of type 1 HRS over time. METHODS: We performed a systematic review and meta-analysis for randomized controlled trials (RCTs) comparing type 1 HRS outcomes including (a) overall survival (liver transplant-free survival if reported) and (b) HRS reversal. Each study arm was analyzed separately to look at changes in outcomes over time. RCTs published comparing medical treatments for type 1 HRS were searched using several databases through July 31, 2019. RESULTS: Fourteen RCTs (28 arms) involving 778 participants enrolled between 2002 and 2018 were included. Twelve RCTs measured HRS reversal. In conjunction with albumin (or plasma expander), the most common medications used were terlipressin (13 arms), antibiotics (7), norepinephrine (6), dopamine (4), and midodrine/octreotide (3). Pooled survival rate was 34.6% (95% CI 26.4-43.8), and pooled HRS reversal rate was 42.8% (95% CI 34.2-51.9). Regression analyzing the incremental effect of the year the RCT was initiated showed that more recent studies were not associated with improved survival (OR 1.02, 95% CI 0.94-1.11, p = 0.66) or HRS reversal rates (OR 1.03, 95% CI 0.96-1.11, p = 0.41). There was no survival improvement when RCTs with endpoints assessed ≤ or > 1 month were analyzed separately with respective OR of 1.07 (95% CI 0.95-1.20, p = 0.26) and 0.97 (95% CI 0.85-1.12, p = 0.70). CONCLUSION: Outcomes have not improved for patients with type 1 HRS since 2002. There is a need to improve prevention and treatment of type 1 HRS.
Sujet(s)
Syndrome hépatorénal/traitement médicamenteux , Syndrome hépatorénal/mortalité , Adulte , Albumines/usage thérapeutique , Antibactériens/usage thérapeutique , Dopamine/usage thérapeutique , Association de médicaments , Femelle , Syndrome hépatorénal/étiologie , Humains , Mâle , Adulte d'âge moyen , Midodrine/usage thérapeutique , Norépinéphrine/usage thérapeutique , Octréotide/usage thérapeutique , Substituts du plasma/usage thérapeutique , Essais contrôlés randomisés comme sujet , Analyse de régression , Taux de survie , Terlipressine/usage thérapeutique , Résultat thérapeutique , Vasoconstricteurs/usage thérapeutique , Jeune adulteRÉSUMÉ
BACKGROUND: Hepatorenal syndrome type 1 (HRS-1), a form of acute kidney injury (AKI) in cirrhosis, has a median survival of days to weeks if untreated. The impact of reduction in AKI stage on overall survival in cirrhosis, independent of HRS reversal, is unclear. METHODS: The Randomized, placEbo-controlled, double-blind study to confirm the reVERSal of HRS-1 with terlipressin study assessed terlipressin versus placebo, both with albumin, as treatment for HRS-1 for ≤14 days. Renal dysfunction severity was categorized by AKI stage at enrollment. Baseline patient characteristics were evaluated as predictors of AKI improvement using a multivariate model; the association between AKI stage reduction and 90-day survival was assessed using linear regression. RESULTS: A total of 184 patients (terlipressin: n = 91; placebo: n = 93) with similar numbers in AKI Stages 1-3 (terlipressin/placebo, Stage 1: n = 25/26; Stage 2: n = 35/33; Stage 3: n = 31/34) were included. Predictors of AKI improvement were absence of alcoholic hepatitis, baseline serum creatinine and male gender. Overall survival was not significantly different across AKI stages (range 53-65%). In patients with no AKI worsening, 90-day survival was consistently better when AKI improved independent of HRS reversal, regardless of the initial AKI stage, with patients with Stage 1 at initial diagnosis achieving the greatest clinical benefit. A significant association was observed between AKI reduction and overall 90-day survival (P = 0.0022). CONCLUSIONS: A reduction in AKI stage, independent of HRS reversal, was sufficient to improve overall survival in patients with HRS-1. The goal for HRS-1 treatment should be less stringent than absolute HRS reversal.
Sujet(s)
Atteinte rénale aigüe/mortalité , Atteinte rénale aigüe/anatomopathologie , Syndrome hépatorénal/mortalité , Terlipressine/usage thérapeutique , Vasoconstricteurs/usage thérapeutique , Atteinte rénale aigüe/prévention et contrôle , Sujet âgé , Méthode en double aveugle , Femelle , Syndrome hépatorénal/traitement médicamenteux , Syndrome hépatorénal/anatomopathologie , Humains , Mâle , Adulte d'âge moyen , Pronostic , Taux de survieSujet(s)
Atteinte rénale aigüe/diagnostic , Atteinte rénale aigüe/traitement médicamenteux , Albumines/usage thérapeutique , Syndrome hépatorénal/diagnostic , Syndrome hépatorénal/traitement médicamenteux , Terlipressine/usage thérapeutique , Vasoconstricteurs/usage thérapeutique , Atteinte rénale aigüe/complications , Atteinte rénale aigüe/mortalité , Association de médicaments , Syndrome hépatorénal/étiologie , Syndrome hépatorénal/mortalité , Humains , Estimation de Kaplan-Meier , Guides de bonnes pratiques cliniques comme sujet , Études rétrospectives , Résultat thérapeutiqueRÉSUMÉ
Background: Patients with hepatorenal syndrome carry a high short-term mortality. Early diagnosis and treatment are essential for patients' outcome. Nevertheless diagnosis of HRS remains difficult. First-line therapy terlipressin is often associated with severe complications. Biomarkers become more on focus for an early diagnosis. Objective: The aim of this study was to test the diagnostic accuracy of urinary [TIMP-2]·[IGFBP7] for HRS patients and prognostic value for therapy responding patients. Material and methods: NephroCheck® measures urinary concentrations of TIMP-2 and IGFBP-7, both indicating stress of renal cells and associated with induction of cell cycle arrest. 22 HRS patients and 30 patients with normal kidney function were included. [TIMP-2]·[IGFBP7] was measured using NephroCheck®. HRS patients receiving terlipressin were also examined. Results: [TIMP-2]·[IGFBP7] values did not differ significantly (1.3 ± 2.09 vs. 1.03 ± 1.03; p = 0.55). Furthermore, there was no significant difference of [TIMP-2]·[IGFBP7] regarding response of terlipressin (1.32 ± 2.39 vs. 0.81 ± 1.05; p = 0.56). Low [TIMP-2]·[IGFBP7] values were significantly associated with higher mortality (p = 0.01). Conclusions: The results of this study suggest that [TIMP-2]·[IGFBP7] is not suitable for diagnostic of HRS and prediction of therapy response, but there might be evidence for prognostic value of [TIMP-2]·[IGFBP7] in regard to mortality of liver cirrhosis patients.
Sujet(s)
Points de contrôle du cycle cellulaire , Syndrome hépatorénal/diagnostic , Syndrome hépatorénal/mortalité , Protéines de liaison aux IGF/urine , Inhibiteur tissulaire de métalloprotéinase-2/urine , Marqueurs biologiques/urine , Diagnostic précoce , Femelle , Syndrome hépatorénal/anatomopathologie , Syndrome hépatorénal/urine , Humains , Mâle , Adulte d'âge moyen , PronosticRÉSUMÉ
Background: Hepatorenal syndrome (HRS) is associated with a poor prognosis. In HRS type 1, loss of renal function is rapidly progressive, while HRS type 2 is characterised by chronic ascites and more moderately elevated renal parameters. While treatment with terlipressin/albumin is well established in type 1, its effectiveness in chronic HRS is less clear. Objective: The aim of this study was to evaluate the effectiveness of terlipressin/albumin treatment in patients with HRS type 2. Methods: All patients with a first episode of HRS between April 2013 and February 2016 were included in this observational study. Relevant clinical and laboratory parameters were recorded and patients were followed. Results: A total of 106 patients with HRS were included. With terlipressin therapy reversal of HRS types 1 and 2 was achieved in 48% and 46% of patients (p = 0.84) with relapse rates of 8% vs 50% (p = 0.001). Overall survival (OS) and survival free of liver transplantation (LTx) were similar in HRS types 1 and 2 (p = 0.69; p = 0.64). In multivariate analysis response to treatment was independently associated with better OS in HRS type 2, in addition to established risk factors such as lower Model for End-Stage Liver Disease score, absence of hepatic encephalopathy and eligibility for LTx. Conclusion: A terlipressin treatment course seems to be justified in selected patients with HRS type 2, especially in countries and settings with long transplant waiting lists. In addition treatment response might also help to identify HRS type 2 patients with a more favourable outcome.
Sujet(s)
Albumines/usage thérapeutique , Syndrome hépatorénal/traitement médicamenteux , Cirrhose du foie/complications , Terlipressine/usage thérapeutique , Vasoconstricteurs/usage thérapeutique , Sujet âgé , Association de médicaments/méthodes , Femelle , Études de suivi , Syndrome hépatorénal/étiologie , Syndrome hépatorénal/mortalité , Syndrome hépatorénal/anatomopathologie , Humains , Estimation de Kaplan-Meier , Cirrhose du foie/mortalité , Cirrhose du foie/chirurgie , Transplantation hépatique/statistiques et données numériques , Mâle , Adulte d'âge moyen , Récidive , Induction de rémission/méthodes , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Several lines of evidence indicate that decompensated cirrhosis is characterized by the presence of systemic inflammation. Hepatorenal syndrome (HRS-AKI) is a unique type of renal failure that occurs at late stages of cirrhosis. However, confirmation of the presence and significance of such inflammatory response in HRS-AKI is lacking. AIM AND METHODS: To characterize the systemic inflammatory response, as estimated by measuring a large number of cytokines, in 161 patients hospitalized for an acute decompensation of cirrhosis: 44 patients without acute kidney injury (AKI), 63 patients with hypovolaemia-induced AKI and 58 patients with HRS-AKI. RESULTS: HRS-AKI was characterized by an altered cytokine profile compared to the other two groups, particularly IL-6, IL-8, TNF-α, VCAM-1, fractalkine and MIP-1α. The inflammatory response was not related to presence of bacterial infection, concomitant acute-on-chronic liver failure or severity of renal dysfunction. Patients who responded to terlipressin and albumin had only a decrease in TNF-α and RANTES after treatment without changes in other cytokines. Interestingly, patients with persistent HRS-AKI had higher levels of IP-10 and VCAM-1 compared to those with resolution of HRS-AKI. VCAM-1 was also an independent predictor of 3-month mortality. A systems biology analysis approach showed that the inflammatory status of HRS-AKI was similar to that of chronic nonhepatic inflammatory conditions, such as lupus erythematosus or inflammatory bowel disease. CONCLUSION: Hepatorenal syndrome is characterized by a marked systemic inflammatory state, reminiscent of that of nonhepatic inflammatory diseases, that correlates with patient outcomes.
Sujet(s)
Atteinte rénale aigüe/mortalité , Insuffisance hépatique aigüe sur chronique/complications , Cytokines/sang , Syndrome hépatorénal/mortalité , Cirrhose du foie/complications , Atteinte rénale aigüe/étiologie , Atteinte rénale aigüe/thérapie , Insuffisance hépatique aigüe sur chronique/thérapie , Sujet âgé , Albumines/usage thérapeutique , Marqueurs biologiques/sang , Femelle , Syndrome hépatorénal/étiologie , Syndrome hépatorénal/thérapie , Humains , Inflammation/anatomopathologie , Rein/physiopathologie , Foie/physiopathologie , Cirrhose du foie/thérapie , Transplantation hépatique , Mâle , Adulte d'âge moyen , Études prospectives , Indice de gravité de la maladie , Espagne , Analyse de survie , Terlipressine/usage thérapeutique , Vasoconstricteurs/usage thérapeutiqueRÉSUMÉ
BACKGROUND: Liver disease is a major cause of mortality, with high numbers of hospital deaths, and disproportionately affects people younger than 65 years. This study aims to examine the place of death and factors associated with hospital death for people who died from liver disease. METHOD: We did a national population-based, observational study using the National Death Registration Database from the Office for National Statistics, 2001-14. All non-accidental adult deaths (hospital and non-hospital) from liver disease in England were included. Explanatory variables were underlying cause of death, contributory causes of death (number and specific causes), age at death, sex, marital status, year of death, index of multiple deprivation, rural or urban settlement, and residential region. We applied modified Poisson regression models to assess the strength of association between hospital death and explanatory variables using an adjusted prevalence ratio (PR). FINDINGS: 135â953 decedents were included, of whom 56â065 (41·2%) died from alcohol-related liver disease. Annual deaths from liver disease increased from 7811 in 2001, to 11â017 in 2014. Hospitals were the main place of death (66·9% [95% CI 66·6-67·1]) for patients who died from liver disease. The proportion of hospital deaths reduced from 71·5% in 2001 to 60·0% in 2014. After adjusting for sociodemographic factors, patients who died from alcohol-related liver disease had the highest chance of hospital death; people who died from liver cancer were less likely to die in hospital than people with alcohol-related liver disease (adjusted PR 0·61 [95% CI 0·60-0·61]). People with four or more contributory causes of death were more likely to die in hospital than those with no contributory causes (1·45 [1·42-1·47]). Patients with sepsis (1·24 [1·23-1·25]), hepatorenal syndrome (1·22 [1·21-1·22]), and peritonitis (1·18 [1·17-1·20]) had higher chances of hospital death than those without these respective contributory causes, and those with alcohol-related disorders (0·67 [0·66-0·69]) had lower chances of hospital death. INTERPRETATION: The high risk of hospital death in patients with sepsis, hepatorenal syndrome, or peritonitis warrants further investigation, and the low chance of hospital death in patients with alcohol-related disorders also needs to be explored. Prevention strategies and end-of-life care services are urgently needed to prevent and tackle harms from liver disease. FUNDING: National Institute of Health Research Health Services and Delivery Research Programme, and Collaboration for Leadership in Applied Health Research and Care South London.
Sujet(s)
Mortalité hospitalière , Maladies du foie/mortalité , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Cause de décès , Comorbidité , Angleterre/épidémiologie , Femelle , Syndrome hépatorénal/mortalité , Humains , Maladies alcooliques du foie/mortalité , Tumeurs du foie/mortalité , Mâle , Adulte d'âge moyen , Péritonite/mortalité , Caractéristiques de l'habitat , Sepsie/mortalité , Facteurs socioéconomiques , Jeune adulteRÉSUMÉ
Enterobacteriaceae are now the predominant pathogens isolated in patients with liver cell failure associated with bloodstream infections. We conducted a retrospective cohort study of patients who were admitted for the diagnosis of hepatorenal failure (HRF) between June 1999 and May 2008 to investigate the risk factors of Enterobacteriaceae bacteremia (EB). EB was defined as the isolation of an EB species from at least one blood culture within three months following diagnosis of HRF. Variables were collected from the medical records and analyzed in relation to EB. Twenty-four (32.5%) of the 73 patients developed EB. The origin of EB was abdominal in 21% of the patients, urinary in 12.5%, pulmonary in 16.5%, and primary in the remaining patients (50%). Two-thirds of EB occurred within 10 days following the development of HRF. The main pathogens were Escherichia coli (44%), Enterobacter species (20%) and Klebsiella pneumoniae (22%). Eighteen patients (75%) with EB died. Variables significantly associated with EB after multivariate analysis were a model for end-stage liver disease score >20 [odds ratio (OR): 2.84, P <0.02], posthepatitis B liver cirrhosis (OR: 4.72, P <0.05), posthepatitis C liver cirrhosis (OR: 3.48, P <0.05), and initial level of serum creatinine on admission to intensive care unit (OR: 2.56, P <0.02). EB is a frequent and severe complication of HRF. Patients with posthepatitis cirrhosis B and C, higher serum creatinine, and severe liver cell failure score have a high risk of developing EB.
Sujet(s)
Bactériémie/mortalité , Infections à Enterobacteriaceae/mortalité , Syndrome hépatorénal/mortalité , Bactériémie/diagnostic , Bactériémie/microbiologie , Égypte/épidémiologie , Infections à Enterobacteriaceae/diagnostic , Infections à Enterobacteriaceae/microbiologie , Femelle , Syndrome hépatorénal/diagnostic , Humains , Mâle , Adulte d'âge moyen , Pronostic , Études rétrospectives , Appréciation des risques , Facteurs de risque , Facteurs tempsRÉSUMÉ
BACKGROUND: The role of nonselective beta-blockers in cirrhotic patients with ascites has been recently questioned; however, definitive evidence in this regard is still lacking. AIMS: To analyze published data on the influence of nonselective beta-blockers as compared to control group on survival of cirrhotic patients with ascites. METHODS: Computerized bibliographic search on the main databases was performed. Hazard ratios from Kaplan-Meier curves were extracted in order to perform an unbiased comparison of survival estimates. Secondary outcomes were mortality in patients with refractory ascites, pooled rate of nonselective beta-blockers interruption, spontaneous bacterial peritonitis and hepato-renal syndrome incidence. RESULTS: Three randomized controlled trials and 13 observational studies with 8279 patients were included. Overall survival was comparable between the two groups (hazard ratio = 0.86, 0.71-1.03, p = 0.11). Study design resulted as the main source of heterogeneity in sensitivity analysis and meta-regression. Mortality in refractory ascites patients was similar in the two groups (odds ratio = 0.90, 0.45-1.79; p = 0.76). No difference in spontaneous bacterial peritonitis (odds ratio = 0.78, 0.47-1.29, p = 0.33) and hepato-renal syndrome incidence (odds ratio = 1.22, 0.48-3.09; p = 0.67) was observed. Pooled rate of nonselective beta-blockers interruption was 18.6% (5.2-32.1%). CONCLUSIONS: Based on our findings, nonselective beta-blockers should not be routinely withheld in patients with cirrhosis and ascites, even if refractory.
Sujet(s)
Antagonistes bêta-adrénergiques/usage thérapeutique , Ascites/traitement médicamenteux , Cirrhose du foie/traitement médicamenteux , Antagonistes bêta-adrénergiques/effets indésirables , Ascites/étiologie , Ascites/mortalité , Loi du khi-deux , Syndrome hépatorénal/étiologie , Syndrome hépatorénal/mortalité , Humains , Incidence , Estimation de Kaplan-Meier , Cirrhose du foie/complications , Cirrhose du foie/mortalité , Odds ratio , Péritonite/microbiologie , Péritonite/mortalité , Facteurs de risque , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND AND AIMS: This study aimed to create a risk scoring model for death from cirrhosis and hepatorenal syndrome, improve the detection rate of high-risk groups, and provide clinical evidence for early intervention treatment. PATIENTS AND METHODS: We retrospectively recruited 196 patients with cirrhosis and hepatorenal syndrome between 1 January 2013 and 31 July 2014 at Beijing Ditan Hospital, Capital Medical University, China. The clinical information, biochemical values, age, and sex of the patients were included in the multivariate logistic regression model for screening independent risk factors. The model was validated in 56 patients with cirrhosis and hepatorenal syndrome between 1 August 2014 and 31 December 2014 at Beijing Ditan Hospital, Capital Medical University, China. RESULTS: The death risk prediction scoring model included the following four independent risk factors: liver cancer, neutrophil above 70%, alanine aminotransferase higher than 40 U/l, and creatinine higher than 127 mmol/l. The sum death risk score ranged from 0 to 5: 0-2 identified patients with a lower risk of death (mortality rates: 12-41.4%), whereas 3-5 identified patients with a higher risk of death (mortality rates: 48.8-80%). Receiver-operating characteristic curves were constructed for the scoring model and the areas under the curves (AUC) were compared using the z-test. The AUC of the scoring model was 0.843. In addition, the AUC of validated model in 56 patients was 0.742. CONCLUSION: The scoring model can accurately predict mortality risk in patients with hepatorenal syndrome.
Sujet(s)
Techniques d'aide à la décision , Syndrome hépatorénal/mortalité , Cirrhose du foie/mortalité , Adulte , Sujet âgé , Alanine transaminase/sang , Aire sous la courbe , Marqueurs biologiques/sang , Carcinome hépatocellulaire/mortalité , Loi du khi-deux , Chine , Créatinine/sang , Femelle , Syndrome hépatorénal/sang , Syndrome hépatorénal/diagnostic , Humains , Numération des leucocytes , Cirrhose du foie/sang , Cirrhose du foie/diagnostic , Tumeurs du foie/mortalité , Modèles logistiques , Mâle , Adulte d'âge moyen , Analyse multifactorielle , Granulocytes neutrophiles , Odds ratio , Valeur prédictive des tests , Pronostic , Modèles des risques proportionnels , Courbe ROC , Reproductibilité des résultats , Études rétrospectives , Appréciation des risques , Facteurs de risqueRÉSUMÉ
Tubular dysfunction is an important feature of renal injury in hepatorenal syndrome (HRS) in patients with end-stage liver disease. The pathogenesis of kidney injury in HRS is elusive, and there are no clinically relevant rodent models of HRS. We investigated the renal consequences of bile duct ligation (BDL)-induced hepatic and renal injury in mice in vivo by using biochemical assays, real-time polymerase chain reaction (PCR), Western blot, mass spectrometry, histology, and electron microscopy. BDL resulted in time-dependent hepatic injury and hyperammonemia which were paralleled by tubular dilation and tubulointerstitial nephritis with marked upregulation of lipocalin-2, kidney injury molecule 1 (KIM-1) and osteopontin. Renal injury was associated with dramatically impaired microvascular flow and decreased endothelial nitric oxide synthase (eNOS) activity. Gene expression analyses signified proximal tubular epithelial injury, tissue hypoxia, inflammation, and activation of the fibrotic gene program. Marked changes in renal arginine metabolism (upregulation of arginase-2 and downregulation of argininosuccinate synthase 1), resulted in decreased circulating arginine levels. Arginase-2 knockout mice were partially protected from BDL-induced renal injury and had less impairment in microvascular function. In human-cultured proximal tubular epithelial cells hyperammonemia per se induced upregulation of arginase-2 and markers of tubular cell injury. CONCLUSION: We propose that hyperammonemia may contribute to impaired renal arginine metabolism, leading to decreased eNOS activity, impaired microcirculation, tubular cell death, tubulointerstitial nephritis and fibrosis. Genetic deletion of arginase-2 partially restores microcirculation and thereby alleviates tubular injury. We also demonstrate that BDL in mice is an excellent, clinically relevant model to study the renal consequences of HRS. (Hepatology 2018; 00:000-000).
Sujet(s)
Atteinte rénale aigüe/métabolisme , Arginine/métabolisme , Syndrome hépatorénal/anatomopathologie , Tubules rénaux/anatomopathologie , Nitric oxide synthase/métabolisme , Atteinte rénale aigüe/anatomopathologie , Atteinte rénale aigüe/physiopathologie , Animaux , Marqueurs biologiques/métabolisme , Ponction-biopsie à l'aiguille , Modèles animaux de maladie humaine , Évolution de la maladie , Syndrome hépatorénal/mortalité , Syndrome hépatorénal/physiopathologie , Humains , Immunohistochimie , Tubules rénaux/métabolisme , Mâle , Souris , Souris de lignée C57BL , Souris knockout , Répartition aléatoire , Appréciation des risques , Sensibilité et spécificité , Indice de gravité de la maladie , Taux de survieRÉSUMÉ
BACKGROUND: The aim of this study was to predict the occurrence of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and ascites. PATIENTS AND METHODS: We retrospectively evaluated 2-year data of 78 patients with cirrhosis and ascites (Child-Pugh B/C: 45/43). The mean arterial pressure (MAP) and cardiac output (CO) were measured in all patients just before administration of 2 mg of terlipressin and 30 min later. Systemic vascular resistance (SVR) was calculated as MAP/CO. ΔMAP, and ΔCO, and ΔSVR were defined as the percentage change of MAP, CO, and SVR, respectively, after terlipressin injection. Plasma renin activity (PRA) and plasma aldosterone were evaluated at baseline. Two multivariate models were used: one excluding (model 1) and one including (model 2) the Model of End-stage Liver Disease score. RESULTS: Higher ΔSVR, Model of End-stage Liver Disease score, and PRA were related independently to the severity of cirrhosis. Independent predictors of HRS at 12 and 24 months were ΔSVR (models 1/2: P=0.008/0.01 and 0.01/0.02, respectively), ΔCO (models 1/2: P=0.01/0.03 and 0.03/0.04, respectively), and PRA (models 1/2: P=0.04 and model 1: P=0.04, respectively). ΔSVR at 12 and 24 months (models 1/2: P=0.005/0.01 and 0.01/0.03, respectively) and ΔCO at 24 months (models 1/2: P=0.02/0.01, respectively) were related independently to survival. Patient groups with significantly higher probability of HRS and mortality were identified by certain cutoffs of ΔSVR (20.6 and 22.8%, respectively) and ΔCO (-10.6 and -11.8%, respectively). ΔSVR and ΔCO independently predicted survival in patients with the most advanced cirrhosis and infection-related survival. CONCLUSION: An increase in SVR by at least 20% and a decrease in CO at least 10% in response to terlipressin could predict HRS and mortality in patients with advanced cirrhosis.